» Articles » PMID: 14505800

Tumor Acidity, Ion Trapping and Chemotherapeutics. I. Acid PH Affects the Distribution of Chemotherapeutic Agents in Vitro

Overview
Date 2003 Sep 25
PMID 14505800
Citations 132
Authors
Affiliations
Soon will be listed here.
Abstract

Resistance to anti-cancer chemotherapies often leads to regional failure, and can be caused by biochemical and/or physiological mechanisms. Biochemical mechanisms include the overexpression of resistance-conferring proteins. In contrast, physiological resistance involves the tumor microenvironment, and can be caused by poor perfusion, hypoxia and/or acidity. This communication investigates the role of tumor acidity in resistance to a panel of chemotherapeutic agents commonly used against breast cancer, such as anthracyclines, taxanes, anti-metabolites and alkylating agents. The effects of pH on the cytotoxicity of these agents were determined, and ion trapping was confirmed by monitoring the effect of pH on the cellular uptake of radiolabeled anthracyclines. Furthermore, pH-dependent cytotoxicity and uptake were compared between parental drug sensitive MCF-7 cells and variants overexpressing p-glycoprotein (MDR-1) and Breast Cancer Resistance Protein. These data indicate that the magnitude of physiological resistance from pH-dependent ion trapping is comparable to biochemical resistance caused by overexpression of drug efflux pumps. Hence, microenvironment-based ion trapping is a significant barrier to anthracycline-based chemotherapy and can itself be a therapeutic target to enhance the efficacy of existing chemotherapies.

Citing Articles

Tumor microenvironment targeted nano-drug delivery systems for multidrug resistant tumor therapy.

Shao X, Zhao X, Wang B, Fan J, Wang J, An H Theranostics. 2025; 15(5):1689-1714.

PMID: 39897552 PMC: 11780529. DOI: 10.7150/thno.103636.


Acidic Microenvironment Enhances Cisplatin Resistance in Bladder Cancer via Bcl-2 and XIAP.

Hiruma K, Bilim V, Kazama A, Shirono Y, Murata M, Tomita Y Curr Issues Mol Biol. 2025; 47(1.

PMID: 39852158 PMC: 11763506. DOI: 10.3390/cimb47010043.


Spatial transcriptomics in breast cancer reveals tumour microenvironment-driven drug responses and clonal therapeutic heterogeneity.

Jimenez-Santos M, Garcia-Martin S, Rubio-Fernandez M, Gomez-Lopez G, Al-Shahrour F NAR Cancer. 2024; 6(4):zcae046.

PMID: 39703753 PMC: 11655296. DOI: 10.1093/narcan/zcae046.


Enhanced Delivery and Potency of Chemotherapeutics in Melanoma Treatment via Magnetite Nanobioconjugates.

Diaz E, Quezada V, Cifuentes J, Arias Morales N, Reyes L, Munoz-Camargo C ACS Omega. 2024; 9(45):45402-45420.

PMID: 39554413 PMC: 11561594. DOI: 10.1021/acsomega.4c07415.


Biochemical hallmarks-targeting antineoplastic nanotherapeutics.

Han J, Dong H, Zhu T, Wei Q, Wang Y, Wang Y Bioact Mater. 2024; 36:427-454.

PMID: 39044728 PMC: 11263727. DOI: 10.1016/j.bioactmat.2024.05.042.